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 glucose, left ventricular weight, or body weight but nearly 
doubled absolute and relative capillary densities compared 
to untreated controls (1.2 vs. 0.6 capillaries/myocyte in heart 
and 1.5 vs. 0.9 capillaries/myocyte in quadriceps muscle) af-
ter 13 weeks of diabetes. No antiapoptotic or angiogenic in-
fluence of pioglitazone was detected while a reduced ex-
pression of hypoxia-inducible factor-3  and PPAR coactiva-
tor-1  (PGC-1  ) mRNA as well as vascular endothelial growth 
factor (VEGF) protein possibly occurred as a consequence
of improved vascularization.  Conclusion: Pioglitazone pre-
serves microvascular structure in diabetes independently of 
improvements in glycemic control and by a mechanism un-
related to VEGF-mediated angiogenesis. 
 Copyright © 2012 S. Karger AG, Basel 
 Introduction 
 Diabetes is associated with a variety of vascular patho-
logic processes leading to micro- and macrovascular dis-
ease. Microvascular alterations are importantly involved 
in diabetic organ damage, e.g. nephropathy and retinop-
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 Abstract 
 Background/Aims: Reduction of capillary network density 
occurs early in the development of metabolic syndrome and 
may be relevant for the precipitation of diabetes. Agonists
of the peroxisome proliferator-activated receptor (PPAR)-  
transcription factor are vasculoprotective, but their capacity 
for structural preservation of the microcirculation is unclear. 
 Methods: Male Wistar rats were rendered diabetic by strep-
tozotocin and treated with pioglitazone in chow for up to 12 
weeks. Capillary density was determined in heart and skel-
etal muscle after platelet endothelial cell adhesion mole-
cule-1 (PECAM-1) immunostaining. Hallmarks of apoptosis 
and angiogenesis were determined.  Results: Capillary den-
sity deteriorated progressively in the presence of hyper-
glycemia (from 971/mm 2 to 475/mm 2 in quadriceps muscle 
during 13 weeks). Pioglitazone did not influence plasma 
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athy, and include dysregulation, enhanced permeability, 
and pathologic angiogenesis, as well as capillary rarefac-
tion. The latter phenomenon can be differentiated into a 
functional insufficiency of capillary recruitment and a 
structural reduction of capillary density, both of which 
impair tissue perfusion in a reversible or chronic manner, 
respectively  [1] . Structural deterioration of the capillary 
network has consistently been observed in models of type 
2 diabetes and hypertension, the hallmarks of the so-
called ‘metabolic syndrome’  [2, 3] . Interestingly, capillary 
rarefaction is even present in normotensive men with a 
hypertensive disposition  [4] and correlates inversely with 
insulin resistance in nondiabetic men  [5] , thereby sug-
gesting a causal involvement in the precipitation of both 
diseases. Pathomechanisms of metabolic syndrome such 
as an increased demand of vascular perfusion pressure 
and an impairment of metabolite exchange may well be 
attributed to capillary rarefaction which is therefore con-
sidered as a promising target of therapy  [6–8] .
 Activators of the peroxisome proliferator-activated re-
ceptor-  (PPAR-  ) transcription factor, e.g. the thiazoli-
dinediones (TZDs), increase insulin sensitivity and there-
fore ameliorate hyperglycemia in type 2 diabetes. Apart 
from this, TZDs display a broad spectrum of activities, 
most of which are therapeutically beneficial and associ-
ated with anti-inflammatory and vasoprotective mecha-
nisms  [9] . It has been proposed that reduction in the pro-
gression of type 2 diabetes and of diabetic nephropathy is 
a consequence of such pleiotropic actions of TDZs. Ex-
perimentally, the TZD pioglitazone (PIO) preserves the 
function of glomerular microvessels even in a rat model 
of streptozotocin (STZ)-induced diabetes which excludes 
a concomitant influence on glucose metabolism  [10] . 
Since TZDs increase the availability of nitric oxide 
through direct activation of NO synthase and reduction 
of inflammation  [11] , such treatment may target one ma-
jor pathomechanism of structural diabetic damage of the 
microcirculation  [12] . We therefore hypothesized that 
treatment with PIO might prevent diabetic capillary rar-
efaction in a manner independent of its antihyperglyce-
mic activity.
 Material and Methods 
 Experimental Protocols 
 All experiments were approved by the Authorities of Schleswig-
Holstein and complied with principles of laboratory animal care. 
A total of 50 male Wistar rats aged 8 weeks (Charles River, Sulz-
feld, Germany) were used in 3 experimental protocols: (1) time 
course of capillary rarefaction (nondiabetic control rats, and rats 
after 5, 7, and 13 weeks of diabetes; n = 5), (2) long-term treatment 
[diabetic rats fed with standard chow (Altromin, Lage, Germany), 
or chow supplemented with 0.01% PIO (Takeda Pharma, Germa-
ny) for 12 weeks; n = 10], and (3) short-term treatment (nondia-
betic control and STZ-diabetic groups, the latter treated with ei-
ther solvent or PIO, 10 mg/kg body weight by gavage for 4 days;
n = 3–4). Diabetes was induced by i.p. injection of STZ (75 mg/kg 
body weight in citrate buffer, 0.1 mol/l, pH 4.5). Blood glucose 
levels were determined 2 days after STZ injection and had to ex-
ceed 22 mmol/l for further inclusion of the animal. Treatments 
with PIO began 8 days after induction of diabetes with the provi-
sion of supplemented chow or once-daily oral application. Blood 
pressure and heart rate were determined by tail plethysmography 
 [13] . Rats were killed by i.p. injection of pentobarbital (100 mg/kg 
body weight).
 Capillary Morphometry  
 Heart and quadriceps femoris muscles were quickly excised 
and cut for the preparation of transverse disks of the left ven-
tricle and the rectus femoris portion which were snap frozen in 
2-methylbutane (–80   °   C). After mounting in Lipshaw embed-
ding matrix, 10-  m-thick slices were generated with a cryotome 
(CM 3050; Leica, Germany). Capillary endothelium was labelled 
with a primary antibody against platelet endothelial cell adhe-
sion molecule-1 (PECAM-1, mouse anti-rat CD31, 1: 1,000; Sero-
tec, USA) which was detected using the Biotin-Streptavidin-
HRP technique (Vectastain Elite ABC; Vector Laboratories, 
Burlingame, Calif., USA). Appropriate negative controls were 
included. Nuclei were counterstained with hemalaun. In each 
sample, 20 fields with an area of 0.0357 mm 2 each were selected 
following the criteria of Weidner  [14] before they were photo-
graphed and analyzed for the number of stained capillaries and 
myocytes. Apoptotic nuclei were visualized in cryosections us-
ing the TUNEL reaction (DeadEnd Fluorometric TUNEL Sys-
tem; Promega, USA).
 Biochemical Analysis 
 Plasma glucose was determined in venous blood using the glu-
cose-oxidase reaction (Elite XL; Bayer, Germany). Urine was sam-
pled from the bladder at the end of the experiment and analyzed 
for albumin by nephelometry (Clinical Laboratory, University 
Clinics, Lübeck, Germany). The activity of caspases 3 and 7 was 
measured in homogenates of quadriceps muscle using a lumines-
cent substrate according to the manufacturer’s recommendations 
(Caspase-Glo 3/7; Promega). Vascular endothelial growth factor 
(VEGF)-A was determined in plasma and in homogenates of 
quadriceps muscle (2 mg protein/ml) using a commercial ELISA 
(Quantikine; R&D Systems, Minneapolis, Minn., USA). mRNA 
was extracted, reversely transcribed, and quantified by real-time 
PCR as previously described  [15] .
 Materials 
 All substances were obtained in highest quality from either 
Sigma (Taufkirchen, Germany) or Merck (Darmstadt, Germany) 
unless stated otherwise.
 Statistics 
 Data were evaluated using Student’s t test or one-way ANOVA 
as appropriate. p  ! 0.05 was considered statistically significant.
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 Results 
 Time Course of Capillary Rarefaction  
 Within 2 days of injection, STZ provoked a prominent 
hyperglycemia that was accompanied by typical symp-
toms of diabetes (glucosuria, polydipsia). During 13 
weeks of diabetes, a slight rise in systolic blood pressure 
(from 104  8 2 to 128  8 3 mm Hg, p  ! 0.05) was observed 
while plasma glucose (604  8 8 mg/dl), body weight (280 
 8 18 g), and left ventricular weight (542  8 40 mg) re-
mained constant. A progressive loss of capillaries oc-
curred in the quadriceps muscle regarding the area den-
sity (from 971  8 86 to 475  8 51 mm –2 after 13 weeks) as 
well as the number of capillaries per myocyte ( fig. 1 ). 
 Microvascular Protection by PIO  
 Rats included in the placebo group of the long-term 
treatment study developed a degree of capillary rarefac-
tion similar to that of the group with 13 weeks of diabetes 
in the kinetics study ( fig. 2 ). Ingestion of PIO for 12 weeks 
in the active treatment group did not influence basic met-
abolic parameters but significantly reduced blood pres-
sure and urinary albumin excretion ( table 1 ). When treat-
ment was begun 8 days after the induction of diabetes, 
PIO consistently attenuated the development of capillary 
rarefaction in skeletal as well as heart muscle ( fig. 1 b) but 
did not fully preserve the capillary density of nondiabet-
ic rats (971  8 86 mm –2 in quadriceps muscle). While PIO 
had no influence on myocyte size in skeletal muscle, it 
slightly decreased the number of myocytes per unit of 
area in the myocardium ( fig. 1 c). Visualization of apop-
tosis in myocardial tissue revealed a very low incidence 
(less than 3 TUNEL-positive cells in each preparation) 
which was restricted to nonmyocytes. Biochemical as-
sessment of caspases 3 and 7 demonstrated an increase in 
the combined activity in the PIO-treated group ( table 1 ). 
The mRNA expression of hypoxia-induced factors and 
their target genes [VEGF, glucose transporter 1 (Glut1), 
endothelial nitric oxide synthase (NOS3)] was not affect-
ed by PIO, with the exception of hypoxia-inducible factor 
(HIF)-3  whose transcript levels were reduced ( table 1 ). 
PIO reduced the abundance of VEGF protein in plasma 
( table 1 ) but induced no significant alteration in quadri-
ceps muscle (63.2  8 7.6 vs. 67.7  8 7.9 pg/mg protein for 
PIO vs. the control group, respectively). The mRNA ex-
pression in quadriceps muscle of further factors with an-
giogenic potential was either unchanged (NOS3) or re-
duced (PPAR coactivator 1  ; PGC-1  ) ( table 1 ).
 Effects of PIO on Apoptosis in Short-Term Diabetes  
 To demonstrate a possible induction of apoptosis early 
in the development of diabetes, rats were rendered dia-
betic for a total of 12 days and treated during the final 4 
days with either PIO or placebo. Again, the incidence of 
TUNEL-positive cells was too low to be quantified mor-
phologically. Compared with a nondiabetic control 
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 Fig. 1. Identification and time course of capillary rarefaction in skeletal and heart muscle. The images depict 
capillaries stained for PECAM-1 (arrows) and nuclei (arrowheads) in the quadriceps femoris muscle ( a ) and the 
left ventricular myocardium ( b ). Scale bars = 20   m.  c The graph demonstrates the decline in the ratio of cap-
illary and myocyte densities in quadriceps femoris muscle in response to a prolonged period of hyperglycemia 
( *  p  ! 0.05 vs. normoglycemic control, n = 5). 
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group, the combined activities of caspases 3 and 7 were 
identical in the skeletal muscle of diabetic animals, and 
PIO developed a tendency to increase caspase activities 
further ( fig.  3 ). Compared to skeletal muscle, caspases 
were slightly more active in the myocardium and likewise 
were not influenced by diabetes or PIO treatment ( fig. 3 ). 
While 12 days of diabetes induced no difference in VEGF 
protein concentration in plasma, the tissue content of 
VEGF in skeletal muscle was reduced in diabetic (142  8 
65 pg/mg protein) compared to nondiabetic rats (360  8 
55 pg/mg protein) and it was diminished even further by 
concomitant treatment with PIO (67  8 2 pg/mg protein).
 Discussion 
 This study is the first to demonstrate that capillary 
rarefaction occurs in the rat model of STZ-induced dia-
betes. Such damage to the microcirculation is a known 
consequence of type 2 diabetes (e.g. in the Zucker rat  [2] ) 
and of hypertension (genetic or induced by glucocorti-
Table 1. G eneral and metabolic parameters of STZ-diabetic rats 
treated for 12 weeks with either placebo or PIO
Placebo PIO
Plasma glucose, mg/dl 59285 588812
Food intake, g/day 42.481.6 40.881.2
Body weight, g 264812 237813
Left ventricular weight, mg 607815 593828
Blood pressure, mm Hg 12582 11483*
Heart rate, bpm 349817 347810
Urinary albumin, mg/l 1448 40 56810*
Plasma VEGF-A, pg/ml 90.185.3 72.882.4*
Caspase activity, U/mg protein 16.381.2 22.182.0*
HIF-1, copies/pg RNA 26.683.8 20.783.6
HIF-2, copies/pg RNA 168816 17489
HIF-3, copies/pg RNA 6.0781.16 2.0480.63*
HIF-1, copies/pg RNA 18.681.0 15.881.3
Glut1, copies/pg RNA 6.6580.32 5.9080.29
VEGF-A, copies/pg of RNA 44.484.1 35.783.7
NOS3, copies/pg RNA 32.581.2 32.881.8
PGC-1, copies/pg RNA 2,6378214 1,9118118*
Ca spase activities and mRNA expression profiles were deter-
mined in quadriceps muscle. n = 10, * p < 0.5 vs. placebo.
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 Fig. 2. Influence of PIO on capillary ( a ) and myocyte ( b ) densities after 13 weeks of induced diabetes. Treatment 
with PIO greatly improved the area densities in the quadriceps femoris muscle and the left ventricular myocar-
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 Fig. 3. Apoptosis in skeletal and heart muscle after 12 days of in-
duced diabetes. Neither an increase in apoptosis in comparison to 
nondiabetic rats nor an influence of PIO treatment could be veri-
fied according to the combined activities of caspases 3 and 7 (n = 
3–4). 
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coids or by inhibition of NO synthesis  [3, 16, 17] ). Togeth-
er with analogous observations in STZ-treated mice  [18, 
19] , the present study indicates a general microvascular 
pathophysiology of hyperglycemia which is independent 
of further diabetic implications, such as hypertension or 
endocrine derangement. Importantly, capillary deterio-
ration in our model proceeds for many weeks so that a 
direct vascular toxic action of STZ, which has a half-life 
of less than 1 h, can be excluded. The development of cap-
illary rarefaction may involve various detrimental fac-
tors, but a pivotal role in diabetes as well as hypertension 
has been ascribed to the abundance of oxygen radicals in 
relation to a reduced NO bioavailability  [12, 20] . This im-
balance may trigger apoptosis of endothelial cells or peri-
cytes either directly or through activation of NF-  B  [21, 
22] . High glucose concentrations in vitro stimulate sev-
eral pathways in endothelial cells that lead to enhanced 
mitochondrial superoxide production, thereby triggering 
specific diabetic alterations  [23] . The causal role of oxy-
gen radicals for the development of capillary rarefaction 
in vivo can be deduced from the protective action of rad-
ical scavengers  [12, 20] .
 Although a variety of vascular actions have been re-
ported for TZDs, little is known about a potential protec-
tion of the microcirculation. Studies in the context of di-
abetes have focused on proangiogenic mechanisms that 
were induced by ischemia or simulated in vitro  [24, 25] . 
In contrast, the present study targeted the deterioration 
of microvascular structure imposed by diabetes alone. 
Since PIO did not influence hyperglycemia in the STZ 
model, its protective action must have resulted from in-
terference with specific downstream targets which most 
likely converge on the relationship of NO and oxygen 
radicals. In the setting of diabetic vasculopathy, TZDs 
have been demonstrated to reduce oxidative stress by ac-
tivation of NO synthase, by suppression of superoxide 
generation and down-regulation of NADPH oxidase, and 
by various anti-inflammatory actions, e.g. inhibition of 
NF-  B in various cell types  [9–11] . The ability of TZDs to 
counteract the sequels of NO deficiency is underlined by 
the observation that rosiglitazone delayed capillary loss 
in a model of pharmacological NO-synthase inhibition 
 [17] . In view of these well-characterized antioxidant ac-
tivities of PPAR-  agonists, it appeared to be obvious that 
these pathways would contribute to vascular protection 
observed in STZ-induced diabetes, so that their further 
delineation was not a primary goal of our in vivo study.
 Instead, our analyses were directed toward the possi-
ble antiapoptotic and proangiogenic components of pro-
tection. Although hyperglycemia has been shown to in-
duce apoptosis of vascular cells  [21, 22] , no increase in 
caspase activity was detected in our study in skeletal or 
ventricular muscle after 12 days of diabetes ( fig. 3 ). This 
may be explained by the chronic presence of hyperglyce-
mia that would enable as little as 10% enhancement of 
apoptosis to produce long-term alterations in the micro-
circulation  [16] . Caspase activation to such little extent 
indeed occurred in skeletal muscle of diabetic rats, but 
the impact of diabetes could not be verified statistically 
( fig. 3 ). Even more surprising, PIO was found to increase 
caspase activities in the skeletal muscle of diabetic rats, 
indicating an increased rate of apoptosis ( table 1 ). This 
contradicts the presumed antiapoptotic action of PIO in 
endothelial cells. However, it cannot be excluded that an 
antiapoptotic influence on a specific cell population 
might have been masked by an increase in apoptosis in 
other tissues since apoptotic nuclei were too infrequent to 
allow an analysis of cell type distribution. In fact, induc-
tion of apoptosis in nonendothelial cells appears quite 
feasible since PPAR-  agonists are known for such ac-
tivities in vascular smooth muscle cells and macrophages 
and may even counteract inflammation in this way  [26, 
27] .
 An alternative explanation for the preservation of cap-
illary numbers by PIO might be related to a proangio-
genic influence. Despite the fact that the vascular patho-
physiology of diabetes includes a proliferative compo-
nent, an insufficiency of compensatory angiogenesis is 
evident as well, as exemplified by an impairment of 
wound healing. Low protein levels of VEGF were associ-
ated with capillary rarefaction in the present study as well 
as in kidneys of diabetic patients  [28] and may originate 
from a deficient response of VEGF expression to stimula-
tion via HIF  [29] . Typically, TZDs stimulate VEGF ex-
pression and improve the angiogenic response to isch-
emia  [24, 30, 31] . However, such activity was observed in 
our study. VEGF concentrations in plasma were rather 
decreased by PIO, and mRNA expression in skeletal mus-
cle showed a parallel, albeit statistically insignificant, ten-
dency ( table 1 ). Since PIO may provoke capillary protec-
tion by restoring the sensitivity of HIF, we investigated 
the mRNA expression of all known   -units of HIF, the 
cofactor HIF-1  , some target genes (VEGF-A, Glut1, 
NOS3), and PGC-1  , the latter being able to induce VEGF 
expression in an HIF-independent manner  [32] . Howev-
er, no evidence was found for an influence of PIO on any 
HIF subtype, with the exception of HIF-3  ( table 1 ). This 
subtype is known to be transcriptionally induced by hy-
poxia and in cardiac failure  [15, 33] and is considered to 
be a negative regulator of typical HIF activities. Taken 
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of TZDs in clinical therapy.
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